Elevated Levels of Cerebrospinal Fluid and Plasma Interleukin-37 in Patients with Guillain-Barré Syndrome
Figure 4
Treatment with IV-Ig significantly reduces the levels of plasma cytokines tested in the drug-responding patients, but not in the drug nonresponders. The concentrations of plasma IL-37 (a), IL-17A (b), IFN-γ (c), and TNF-α (d) were determined at 4 weeks after the treatment and compared with those before the treatment in 16 therapy responders (grey dots) and nine therapy nonresponders (white dots). Data shown are values of individual patients before and after the treatment. GBS (A): patients at acute stage; GBS (R): drug responders; GBS (N): drug nonresponders.
